Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg

PURPOSE: Imatinib is indicated for treatment of CML, GIST, etc. The population pharmacokinetics (popPK) of imatinib in patients under long-term treatment are reported in literature. Data obtained from bioequivalence trials for healthy subjects were used to evaluate the influence of demographic and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Chien, Yi-Han, Würthwein, Gudrun, Zubiaur, Pablo, Posocco, Bianca, Pena, María Ángeles, Borobia, Alberto M., Gagno, Sara, Abad-Santos, Francisco, Hempel, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360108/
https://www.ncbi.nlm.nih.gov/pubmed/35831644
http://dx.doi.org/10.1007/s00280-022-04454-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360108/
https://www.ncbi.nlm.nih.gov/pubmed/35831644
http://dx.doi.org/10.1007/s00280-022-04454-y

Ejemplares similares